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Background: In the era of improving overall survival rates of malignant diseases, the impact of
a previous malignancy (PM) on treatment and outcome of lung cancer (LC) remains unclear.
Methods: We reviewed all LC patients from our institution that were treated from 2004 to 2006
for the occurrence of LC with PM excluding patients with multiple primary LC.
Results: A total of 444 and 2698 LC patients with and without a history of a PM were identified
(prevalence of 14.1%). PM were most often located in breast (15.5%), prostate (14.9%), bladder
(9.0%) and kidney (8.8%). Compared to never smokers, patients with nicotine consumption had
more often a cancer history of prostate, gastrointestinal, and the head-neck region. The me-
dian interval until diagnosis of LC was 72.2 months (range 0e537 months) with most LC diag-
nosed 5 years after PM diagnosis. With a similar distribution of histology, stage and
localization compared to controls, NSCLC patients with PM and stage IV disease showed a
favorable overall survival (p < 0.0001). In contrast, SCLC patients had similar survival curves
(n.s.).dress: Lung Clinic Grosshansdorf, Department of Thoracic Oncology, Wo¨hrendamm 80, D-22927




Lung cancer as second malignancy 911Conclusions: A considerable subgroup of LC patients has a history of PM that may indicate a
favorable prognostic factor. However, these patients should be treated similar to other LC pa-
tients.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Lung cancer remains among the most frequent human
cancers and the leading cause of cancer-related deaths in
the Western civilization with a median overall 5-year sur-
vival of only 15% [1]. Recently, besides the major histology
types small cell lung carcinoma (SCLC) and non-small cell
lung carcinoma (NSCLC), further subgroups have been
identified which may be treated differently. For example,
molecular alterations such as EGFR mutations or evidence
of EML4-ALK translocation indicate distinct molecular pro-
files with impact on clinical outcome [2,3]. To date,
increasing numbers of genes are being identified to have
potential roles in the development of a malignancy
including tumor suppressor genes and DNA-repair genes
[4,5]. Still, the understanding of molecular changes un-
derlying the development of multiple cancers remains
incomplete. Beside environmental factors and exposure to
carcinogenic agents such as nicotine and alcohol, heredi-
tary factors may also play an important role in this regard.
As a hypothesis, presence of two or more malignancies in
one patient may also suggest a specific pattern of molecular
alterations. There is limited clinical information on treat-
ment and outcome of lung cancer patients with a history of
a previous malignancy (PM) [6]. A history of a PM might
hamper the treatment of lung cancer by comorbidities or
side effects caused by previous therapies. Most data re-
ported so far has been generated in the last century and has
been derived from low patient numbers from a long time
period which may render conclusions difficult due to vary-
ing diagnostic procedures and therapeutic options. Hence,
we reviewed our experience with lung cancer as a second
primary malignancy in patients diagnosed and treated in
our institution within a defined and recent time interval.Patients and methods
Using the hospital information system and medical records,
we reviewed all lung cancer patients who were seen in our
institution between January 1st, 2004, and December 31st,
2006, for information on any further malignancies prior to
the diagnosis of lung cancer. Other institutions were con-
tacted for further data on PM being diagnosed elsewhere.
Semi-malignant cancers (e.g. basal cell carcinoma) were
not registered as previous malignancies as these were not
supposed to have influence on prognosis and survival. The
histological diagnosis of lung cancer was made by an
experienced pathologist with the knowledge of the PM. The
independence from the PM was confirmed by immuno-
staining, if necessary.
Data on patients with subsequent malignancies after
diagnosis of lung cancer was excluded in this analysis andhas been published elsewhere [7]. Patients with lung cancer
as sole malignancy served as control group. All patients
were predominantly treated for lung cancer in our clinic.
Upon approval by the local Ethics Committee (S-411/2008),
patients and their treating physicians were contacted, and
the follow-up statuses were completed. The staging of lung
cancer was performed according to the 6th edition of TNM
criteria; however, all data was also analyzed using the 7th
TNM classification. The smoking status was assessed at
diagnosis of lung cancer. In agreement to others [8,9], the
status of a former smoker was defined for patients with
nicotine cessation of at least 6 months. Patients with total
consumption of less than 100 were classified as never-
smokers [10].
Follow-up after therapy of lung cancer
All patients entered a follow-up program with 3-monthly
visits for the first 2 years, 6-monthly visits after 2e5 years
and yearly visits thereafter [11,12]. In addition, SCLC pa-
tients were seen every 2 months for the first year. All
follow-up visits included physical examination, lung func-
tion tests and a chest radiograph. In surgically treated pa-
tients, a CT scan was performed every 6 months for the first
2 years.
Statistical analysis
Quantitative variables were summarized with their mean or
median. Two-sided analysis of variance and the c2-test
were performed where appropriate. The census date was
fixed after a medium follow-up period of 40.9 months for
surviving patients. As end points, we used the date of death
or survival at the last documented contact to the patient.
Overall survival was defined as the interval between dates
of diagnosis and death. Living patients were censored at
the date of last clinical visit. The cause of death was
identified by clinical means, since autopsy could not be
performed on a routine basis. Patients who died of other
causes as lung cancer were also censored. Calculations of
survival were done performing Kaplan Meier analyses.
Throughout, a p-value of <0.05 was considered to be sta-
tistically significant.
Results
A total of 444 lung cancer patients were identified with a
history of a PM other than lung cancer. PM were most often
located in breast (15.5%), prostate (14.9%), bladder (9.0%),
and kidney (8.8%) (Table 1). Moreover, a control set was
identified comprising 2698 patients who developed no
previous or subsequent malignancy. At the end of data bank
Table 1 Locations and prevalence of other cancers preceding lung cancer.
Previous malignancy/LC NSCLC SCLC Total Diagnosis >10 yr before LC
n % n % n % n %
Urogenital 70 18.0% 9 13.0% 79 17.8% 19 13.0%
Kidney 35 9.0% 4 6.2% 39 8.8% 9 6.2%
Bladder 35 9.0% 5 6.8% 40 9.0% 10 6.8%
Gastrointestinal 47 12.1% 6 9.6% 53 11.9% 14 9.6%
Esophagus 0 0% 1 0% 1 0.2% 0 0%
Stomach 8 2.1% 1 2.7% 9 2.0% 4 2.7%
Colon 30 7.7% 2 4.8% 32 7.2% 7 4.8%
Rectum 8 2.1% 2 2.1% 10 2.3% 3 2.1%
Gall bladder 1 0.3% 0 0% 1 0.2% 0 0%
Gynecological 90 23.1% 10 32.2% 100 22.5% 47 32.2%
Breast 63 16.2% 6 21.9% 69 15.5% 32 21.9%
Ovary 1 0.3% 0 0% 1 0.2% 0 0%
Uterus 12 3.1% 0 4.8% 12 2.7% 7 4.8%
Cervix 14 3.6% 4 5.5% 18 4.1% 8 5.5%
Head and neck 64 16.5% 4 15.8% 68 15.3% 23 15.8%
Oral cavity 12 3.1% 1 13.7% 13 2.9% 2 13.7%
Pharynx 22 5.7% 1 6.2% 23 5.2% 9 6.2%
Palatine Tonsil 4 1.0% 0 0.7% 4 0.9% 1 0.7%
Larynx 26 6.7% 2 7.5% 28 6.3% 11 7.5%
Oropharyngeal
Abdominal 55 14.1% 12 8.9% 67 15.1% 13 8.9%
Hepatocellular 0 0% 0 0% 0 0% 0 0%
Pancreas 1 0.3% 0 0% 1 0.2% 0 0%
Adrenal Gland 0 0% 0 0% 0 0% 0 0%
Prostate 54 13.9% 12 8.9% 66 14.9% 13 8.9%
Various tumors 63 16.2% 14 20.5% 77 17.4% 30 20.5%
Melanoma 16 4.1% 3 4.1% 19 4.3% 6 4.1%
Other skin cancers (including anal) 14 3.6% 2 2.7% 16 3.6% 4 2.7%
Thyroid 4 1.0% 1 2.1% 5 1.1% 3 2.1%
Hodgkin-Lymphoma 8 2.1% 2 4.8% 10 2.3% 7 4.8%
Non-Hodgkin-Lymphoma 12 3.1% 3 3.4% 15 3.4% 5 3.4%
Othersa 9 2.3% 3 3.4% 12 2.7% 5 3.4%
LC: lung cancer; Mo: months; Yr: years.
a Other cancers include 5 testis carcinomas, 3 sarcomas, 1 parotid-carcinoma, 3 CUP (cancer of unknown primary). For patients with LC
after 10 years: 4 testis carcinomas, 1 parotid-carcinoma.
912 N. Reinmuth et al.closure, a total of 6304 person-years (4393 person-years for
males and 1911 person-years for females) of observation
after diagnosis of lung cancer were noted. Characteristics
of patients with and without a PM are displayed (Table 2).
Since data on treatment of previous malignancies was
sparse and heterogeneous, this factor could not be included
in our subsequent analyses.
In 329 of total 444 patients with PM (74.1%) the smoking
status could be determined. Similar to controls, most pa-
tients were current (51%) or former smokers (34%) with a
mean exposure of 38.3 pack-years. There was no statisti-
cally significant correlation between smoking status and
PM; however, relative to never smokers, current and former
smokers tend to have more often a history of previous
cancers of the prostate (17.6% versus 4.0%), gastro-
intestinal (13.2% versus 8.0%) and head-neck regions
(16.8% versus 10.0%) (p Z 0.09). Similarly, the total nico-
tine consumption was highest in patients with previous
cancer in the head-neck (median of 59.7 pack years; PY),
gastro-intestinal (57.6 PY) and urogenital regions (48 PY).Of 444 patients with a PM history, 389 and 55 developed
NSCLC and SCLC after a median period of 68.5 and 95.6
months, respectively, resulting in a prevalence of lung
cancer with PM of 14.1% (14.96% for NSCLC and 10.1% for
SCLC). Patients with a previous head-neck cancer tend to
develop more often subsequent NSCLC rather than SCLC
(14.4% versus 5.4%), however, this difference was not sta-
tistically significant (pZ 0.06). Of these 68 patients with a
previous head-neck cancer, 37 (54%) patients developed a
second lung cancer with predominant squamous histology
which was diagnosed as lung cancer based on immunohis-
tochemical and clinical data. Interestingly, a large numbers
of gynecological cancers and Hodgkin lymphomas were
diagnosed more than 10 years before diagnosis of lung
cancer.
Histology, stage distribution, localization of lung pri-
maries and occurrence of metastases were not signifi-
cantly different between investigated patients and
controls (Table 3). In general, the stage-dependent
treatment of lung cancer was similar in both groups
Table 2 Patient characteristics with and without a history
of a previous malignancy (PM).
Characteristics Patients with PM Control group
Patients 444 2698
Age at time of diagnosis of LC
Median Age (yr) 67 64
Age range (yr) 34e85 21e86
Age distribution
29 yr 0 2 (0.1%)
30e39 yr 2 (0.4%) 24 (0.9%)
40e49 yr 21 (4.7%) 238 (8.8%)
50e59 yr 73 (16.4%) 676 (25.1%)
60e69 yr 165 (37.2%) 1040 (38.5%)
70e79 yr 157 (35.4%) 620 (23.0%)
80 yr 26 (5.9%) 98 (3.6%)
Sex
Male 297 (66.9%) 1934 (71.7%)
Female 147 (33.1%) 764 (28.3%)
Smoking status
Current smoker 167 (51%) 1484 (74%)
Former 112 (34%) 376 (19)
Never 50 (15%) 152 (7%)
Unknown 115 686
Mean pack years 38.3 42.8
Interval PMeLC
<1 mo 11 (2.5%)
1e6 mo 33 (7.4%)
6 moe1 yr 18 (4.1%)
1e2 yr 25 (5.6%)
2e5 yr 101 (22.7%)
5e10 yr 105 (23.7%)
>10 yr 151 (34.0%)
LC: lung cancer; Mo: months; Yr: years.
Table 3 Disease and treatment characteristics. FPLC,






NSCLC 389 (87.6) 2210 (81.9)
Adenocarcinoma 195 (50.1%) 1080 (48.9%)
Squamous cell carcinoma 141 (36.3%) 725 (32.8%)
Large cell carcinoma 42 (10.8%) 405 (18.3%)
NOS 11 (2.8%) 0
SCLC 55 (12.4) 488 (18.1)
Stage distribution NSCLC
I 98 (25.1) 551 (24.9)
II 48 (12.4) 169 (7.7)
III 130 (33.5) 734 (33.2)
IV 113 (29.0) 756 (34.2)
Stage distribution SCLC
I 4 (7.3) 36 (7.4)
II 4 (7.3) 11 (2.3)
III 16 (29.0) 227 (46.5)
IV 31 (56.4) 214 (43.9)
Initial treatment
Surgery only 145 (32.7) 595 (22.1)
Radiation therapy only 51 (11.5) 302 (11.2)
Chemotherapy only 69 (15.5) 782 (28.9)
Combination therapy
Surgery and chemotherapy 33 (7.4) 215 (7.9)
Surgery and radiation
therapy
22 (4.9) 132 (4.8)
Radiation therapy
and chemotherapy
61 (13.7) 405 (15.0)
All modalities 28 (6.3) 91 (3.4)
No treatment 35 (7.9) 176 (6.5)
LC: lung cancer; N: numbers; NOS: not otherwise specified; PM:
previous malignancy.
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PM and complete resection of their lung tumor. Patients
with PM who underwent surgery had largely a lobectomy
(46%) or an atypical resection (30%). In contrast, control
patients underwent more often lobectomies (71%), while
atypical resections were done in only 4%. Due to poor
performance status or patient denial approximately 30%
of stage IV patients were not treated with systemic
therapy which was similar in patients with and without
PM. Interestingly, 17.4% and 18.8% of stage IV lung cancer
patients with and without PM underwent surgical treat-
ment, respectively. The 25 patients with stage IV lung
cancer and PM receiving surgery included 18 patients with
single pulmonary metastasis and 1 patient with a solitary
adrenal gland metastasis. All other procedures were done
as palliative surgery. Again, this was similar in the control
group.
Survival
Patients with PM had a median overall survival of 904 days
(control group 543 days, p < 0.0001). Since nearly exclu-
sively all deaths were caused by lung cancer, disease spe-
cific survival was similar to overall survival. The survival
benefit hold true for NSCLC (median survival 1075 daysversus 595 days; p < 0.0001; Fig. 1, Supplementary Table 1)
but not for SCLC patients (386 versus 398 days; n.s.,
Supplementary Table 2). Compared to controls, female
patients with PM had a more improved survival (1399 versus
587 days; p < 0.0001; Fig. 2a) compared to male patients
(677 days versus 531; p Z 0.099; Fig. 2b). However, the
interval between diagnosis of lung cancer and PM had no
significant impact on differences in overall survival be-
tween patients with and without PM (data not shown).
Interestingly, lung cancer patients with a previous gyne-
cological malignancy had a significant better survival
compared to patients with previous gastro-intestinal cancer
(p < 0.001; data not shown).
Separated for stages of disease, patients with and
without PM had a similar overall survival for stage IeIIIB
lung cancers. However, patients with stage IV NSCLC and a
history of PM had a significantly improved median overall
survival (409 versus 276 days; p < 0.0001; Fig. 3) which was
significant for both men (p Z 0.001) and women
(p Z 0.001) (data not shown). When all cancers were
reclassified using the 7th TNM classification, these differ-
ences in survival could be confirmed (p < 0.001, data not
shown).
Figure 1 Survival curves of NSCLC patients with and without
a previous malignancy (PM). Patients with PM had a signifi-
cantly improved overall survival (median survival 1075 days
versus 595 days; p < 0.0001).
914 N. Reinmuth et al.The inclusion of surgical procedures into the treatment
of stage IV NSCLC was associated with significantly better
survival in both patients groups with and without PM
(n Z 22; p < 0.001 and nZ 159; pZ 0.007, respectively).
Still, the survival benefit for stage IV NSCLC patients with
PM compared to controls hold true in both patients with or
without surgery (p < 0.001 and p Z 0.005, respectively).
Again, these findings were similar after tumor stage
reclassification (data not shown).
Patients with three independent tumors
Forty-five of 444 (10.1%) patients (28 male, 17 female)
developed a third malignancy (25 and 20 patients before
and after the diagnosis of lung cancer, respectively)
comprising prostate (n Z 10; 40%), bladder (n Z 5; 20%),
breast (n Z 4; 16%), and second NSCLC tumors (n Z 5;
10%). In these patients, lung cancer was often diagnosed as
stage I and II disease (49% versus 28% for controls). With a
median overall survival of 1617 days patients with three
independent malignancies lived more than three times
longer than control patients (542 days, p < 0.0001).Discussion
Few studies have been undertaken to evaluate the preva-
lence, treatment and outcome of lung cancer patients with
a PM other than lung cancer. In patients with previous head
and neck cancer and subsequent primary bronchial cancer,
a poor prognosis has been reported with the comparison to
literature data of lung cancer patients without PM [13]. As
potential explanations, advanced age, and combined
alcohol and tobacco abuse were raised. In contrast, other
studies have marginally stated that a history of malignant
disease does not influence overall prognosis at least in
elderly patients with NSCLC undergoing surgery; however,
the subsets subjected to survival analysis were small
[14,15]. Recently, in a collective comprising a total of 860patients, an improved 5-year survival rate for lung cancer
patients with PM compared to patients without another
tumor has been described [16]. To unravel this conflicting
data, we conducted the present study on a patient cohort
which, to our knowledge, comprises the largest patient
collective so far.
In the current study, the occurrence of lung cancer with
a PM was 14.1% excluding patients with second lung cancer.
In contrast, other studies reported on lower prevalence
numbers between 8.2% and 10.2% analyzing markedly
smaller patient numbers or defined patient subgroups such
as surgically treated lung cancer patients [17e20]. Still, our
primary selection criterion of recruiting exclusively pa-
tients from our center may have impacted our findings of
the occurrence of lung cancer as second malignancy.
Moreover, patients with a PM history may be screened more
frequently leading to increased detection of lung cancer
[21]. However, the occurrence for NSCLC with PM in our
study of 15% is quite similar to data from Duchateau and
colleagues who reported on a prevalence of 14.7% [16]. In
contrast, the development of SCLC after PM seems to be
lower than for NSCLC which is in congruence to others
[17,19]. Interestingly, some reports noted an increase of
the prevalence of two or more malignancies over the past
decades, possibly due to increase of life expectancy and
better treatment options for both malignant and non-
malignant diseases [16,18,22].
Tobacco consumption has been identified as a major risk
factor of various solid cancers including lung, larynx, oral
cavity, esophagus, colorectal, breast and bladder [23,24].
However, we cannot draw solid conclusions on the impact
of smoking on the development of the PM in our study.
Genetic alterations have often been used to explain mul-
tiple malignancies resulting in the concept of “field can-
cerization” [25]. Consequently, a higher lung cancer
incidence for patients with carcinomas of the head-neck
region or bladder has been noted with cigarette smoking
as a major risk factor [22,25,26]. For example, analyzing
2737 patients with multiple primary cancer within
1975e2002, the relative risk for developing intrathoracic
cancer for patients with larynx and bladder carcinomas was
described as 2.42 (2.08e2.81) and 1.50 (1.2e1.86),
respectively [22]. Similarly in our study, lung cancer pa-
tients experienced a PM of larynx, pharynx, kidney, bladder
and stomach more frequently compared to general cancer
incidence data from 2006 in Germany [21]; however, this
finding was statistically not significant. Moreover, most lung
cancer patients with PM had experienced nicotine con-
sumption which was most evident in previous cancers of
these areas.
In congruence to data from others, the majority of our
patients developed lung cancer more than 5 years after the
PM resulting in a higher median age at diagnosis of lung
cancer compared to controls [16,18]. However, the stage
distribution of patients diagnosed with lung cancer within
or after 5 years of occurrence of the PM was not signifi-
cantly different. Still, follow-up programs of selected solid
cancers should consider the development of lung carci-
nomas even after a longer period of time.
In our study, patients with a history of PM and stage
IeIIIB lung cancer had an outcome similar to control pa-
tients which, in turn, demonstrated comparable results in
Figure 2 Gender differences for survival for lung cancer
patients. A) Female patients with a previous malignancy (PM)
had a significantly improved overall survival compared to fe-
male controls (median 1399 versus 587 days; p < 0.0001). B) In
comparison, the overall survival benefit for male lung cancer
patients with PM was less distinctive and missed statistical
significance (median 677 versus 531 days; p Z 0.099).
Figure 3 Overall survival of stage IV NSCLC patients. Patients
with a history of a previous malignancy (PM) demonstrated a
significantly better overall survival compared to controls (me-
dian 409 versus 276 days; p < 0.0001).
Lung cancer as second malignancy 915relation to published data [27e29]. Regarding stage specific
treatment modalities, no significant differences were found
which is in congruence to others [16]. However, atypical
resections were performed more often in patients with PM
while lobectomy was the most frequent surgical method in
control patients. In patients with stage IV NSCLC, a history
of PM seems to be a favorable prognostic factor. This finding
which is somewhat confirmed by the favorable outcome of
patients with three independent tumors may be explained
by several hypotheses: For example, metastatic disease
may rather reflect the biology of the disease compared to
lower stages which is generally treated with surgery or ra-
diation. Also, various epigenetic and genetic alterations are
known to modify lung cancer risk and development [5,30].
Hence, the better overall survival of patients with PM may
indicate a distinct epigenetic profile. Finally, the origin of
the previous malignancy may further influence the course
of subsequent lung cancer since a previous gynecological
malignancy was correlated with a better survival comparedto lung cancer patients with previous gastrointestinal can-
cers. However, one needs to consider the small patient
numbers for this finding. Also, these hypotheses would be
needed to be addressed in preclinical models with the focus
also on epigenetic marks and gene expression changes.
Moreover, since data on performance status was not avail-
able, a possible bias cannot be excluded.
As an additional finding, patient treated with surgery
had a favorable outcome in both stage IV NSCLC patients
with and without PM. While some patients with stage IV
would have been classified as stage III according to current
staging criteria this finding may encourage to conduct
further studies addressing the role of surgery in stage IV
disease. For some patients with single adrenal gland
metastasis or limited number of cerebral secondaries, a
potential benefit from complete resection of both lung
primary and metastasis as a curative approach has been
suggested [31,32]. Whether palliative resection may be
indicated for highly selected stage IV NSCLC patients re-
mains speculative.
Conclusion
In conclusion, presence of PM should be treated similar to
lung cancer as single malignancy. Despite to the unfavor-
able fact of having developed a second cancer, a history of
PM does not significantly impair treatment options and
outcome of lung cancer but may be even associated with an
improved survival.
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